KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40712928无 PMCID2025-Oct0.95This is an original Phase III randomized trial in breast cancer, but it evaluates a radiotherapy technique (boost strategy), not a drug-containing intervention. Furthermore, the primary outcome is patient-reported adverse events/quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.).无 KM 图
Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。PMID 40726438PMC124092442025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial.Epilepsy Behav入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40737960无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.Nat MedPMID 40750932PMC125327092025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.Int J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40750941无 PMCID2025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Effectiveness of an active behavioural physiotherapy intervention (ABPI) for chronic non-specific neck pain: an internal pilot cluster-randomised double-blind clinical trial.Musculoskelet Sci Pract入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40753854无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40758955无 PMCID2025-Oct0.85Study is a Phase III randomized trial of radiotherapy (with or without focal boost) for prostate cancer, meeting oncology, human, randomized, phase, and time-to-event criteria. However, it lacks a drug-containing intervention (the intervention is radiotherapy dose escalation, not a systemic drug). Therefore, it is ineligible per the requirement for a drug-containing intervention.无 KM 图
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients.Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40759266无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma.J AsthmaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40767333无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.Adv Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40768190PMC124746442025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.Nat Med已检查 10 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other;Extended Data Fig. 3:AI 判定为 other;另有 5 张未列出。PMID 40770082PMC125325872025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.Sleep Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:AI 判定为 other;Fig. 2.:森林图/亚组分析图;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other。PMID 40774158PMC127203982025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.CNS Drugs已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:ROC 图;Fig. 3:ROC 图;Fig. 4:森林图/亚组分析图。PMID 40775196PMC124232332025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.Neurol SciPMID 40775552PMC124888382025-Oct0.98未发现恶性肿瘤人群证据。已完成
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40796015无 PMCID2025-Oct0.85The publication reports results of a radiotherapy quality assurance procedure (delineation benchmark case) for the MIRAGE phase III trial. It does not present the trial's primary or secondary time-to-event efficacy results (e.g., OS, PFS). It is an original result report but focuses on methodology, not the efficacy outcomes needed for this cohort.无 KM 图
Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes: Post hoc analysis of ONWARDS 5.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40803997PMC124091982025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40825340无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40825443无 PMCID2025-Oct0.85Report is a secondary analysis of radiotherapy quality assurance from a Phase III trial. While it meets basic eligibility criteria (oncology, human, randomized, phase 3, drug intervention), it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It is an original report of a sub-study focusing on compliance and quality assurance, not the primary efficacy analysis.无 KM 图
Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR.Adv Ther已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 40828352PMC124747332025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.Thyroid疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40828665无 PMCID2025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40834567无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis.Clin Exp Nephrol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40839334PMC124640932025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.J Comp Eff ResPMID 40843507PMC124659482025-Oct0.98未发现恶性肿瘤人群证据。已完成
Clinical Presentation, Biomarker Trajectories, and Outcomes in Women and Men Hospitalized for Acute Heart Failure.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40845614无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40846621无 PMCID2025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis.Ann Rheum DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40849269无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40854315无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40857999无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.Oral Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40884854无 PMCID2025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan.Int J Clin OncolPMID 40888992PMC124745792025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:AI 判定为 other;Figure 3:非 KM 图。PMID 40921169PMC124793902025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).Antimicrob Agents Chemother已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 other。PMID 40924001PMC124868422025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40945523无 PMCID2025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40953572无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40956259无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40974872无 PMCID2025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis.NEJM EvidPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40985784无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.Future Oncol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 40995949PMC125200952025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial.Eur Urol Oncol入排复审未纳入:The record describes a Phase 2/3 randomized controlled trial in oncology (prostate cancer) but does not report any survival, progression, recurrence, death, hazard, time-to-event, or closely related efficacy outcomes. The reported results are diagnostic (stage migration) and do not meet the efficacy outcome requirement for inclusion.PMID 40998687无 PMCID2025-Oct0.90The record describes a Phase 2/3 randomized controlled trial in oncology (prostate cancer) but does not report any survival, progression, recurrence, death, hazard, time-to-event, or closely related efficacy outcomes. The reported results are diagnostic (stage migration) and do not meet the efficacy outcome requirement for inclusion.无 KM 图
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41027802无 PMCID2025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.ESMO Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:生活质量量表图。PMID 41033280PMC125145042025-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies.Clin Transl Sci入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41036707PMC124897422025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41038184无 PMCID2025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of a Generic Clevidipine in Hypertensive Urgencies and Non-Fulminant Hypertensive Emergencies: A Phase III, Multicenter, Randomized, Double-Blind, Positive Drug Parallel-Controlled Study.J Clin Hypertens (Greenwich)PMID 41085098PMC125194232025-Oct0.98未发现恶性肿瘤人群证据。已完成
OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial.CephalalgiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41091731无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.CephalalgiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41091746无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.Expert Opin Biol TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41100115无 PMCID2025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine.J Med Virol已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。PMID 41117170PMC125385302025-Oct0.98未发现恶性肿瘤人群证据。无 KM 图
Development of a Novel Machine Learning Method for Estimation of Life-Long Chronic Disease Progression and Its Application to Type 2 Diabetes.Clin Transl SciPMID 41127917PMC125473602025-Oct0.98未发现恶性肿瘤人群证据。已完成
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.ESMO OpenPMID 41139117PMC125735032025-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成